^
Association details:
| Biomarker: | FGFR2 overexpression |
|---|---|
| Cancer: | Gastrointestinal Cancer |
| Drug: | derazantinib (ARQ 087) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The FGFR-inhibitor derazantinib (DZB) is active in PDX-models of GI-cancer with specific aberrations in FGFR.
Published date:
01/23/2020
Excerpt:
Known driver-mutations were associated with partial-responses (best dT/C = 0.42), but models with FGFR-fusions, especially FGFR2-fusions, were very sensitive leading to stasis or strong-regression, particularly in gastric cancer. High-expression of FGFR2 was also associated with strong responses….DZB showed convincing activity in GIC-models with FGFR-fusions and/or high expression.
